Table 1 Baseline patient, disease, and transplantation characteristics.
Characteristics | N, total 79 (%) |
|---|---|
Median age at diagnosis in years (range) | 56 (19–73) |
Median age at HCT in years (range) | 58 (19–73) |
Female gender | 32 (41) |
Myelofibrosis type | |
Primary | 54 (68) |
Post-ET/Post-PV | 25 (32) |
DIPSS category | |
Low/intermediate-1 | 4 (5) |
Intermediate-2 | 71 (90) |
High | 4 (5) |
RBC transfusion dependence at HCT | 54 (68) |
Platelet transfusion dependence at HCT | 10 (13) |
High-risk cytogenetics at SCT (n = 68) | 16 (24) |
JAK2 mutation (n = 76) | |
Positive | 41 (52) |
Negative | 35 (44) |
JAK inhibitor treatment prior to HCT | 24 (31) |
Conditioning regimen: | |
Myeloablative | 14 (18) |
Reduced intensity | 65 (82) |
Anti-thymocyte globulin administered | 33 (42) |
Donor source: | |
Matched related | 36 (46) |
Others | 43 (54) |
Graft type: | |
Peripheral blood | 77 (97) |
Bone marrow | 2 (3) |
Graft vs. host disease prophylaxis: | |
Calcineurin inhibitor + Methotrexate | 56 (71) |
Calcineurin inhibitor + Mycophenolate | 20 (25) |
Other | 3 (4) |
ABO incompatibility (n = 75): | |
None (Compatible) | 43 (57) |
Minor | 19 (25) |
Major | 12 (16) |
Bidirectional | 1 (1) |
